Urteste SA (URT) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.182x

Based on the latest financial reports, Urteste SA (URT) has a cash flow conversion efficiency ratio of -0.182x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-4.33 Million ≈ $-1.19 Million USD) by net assets (zł23.79 Million ≈ $6.55 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See URT equity to assets ratio to measure how much of total assets are equity-financed.

Urteste SA - Cash Flow Conversion Efficiency Trend (2019–2025)

This chart illustrates how Urteste SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check URT capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.

Urteste SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Urteste SA ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
GLORY HEALTH IND. HD-001
F:84R
N/A
Artmarket.com SA
PA:PRC
0.031x
Volitionrx Ltd
NYSE MKT:VNRX
0.154x
Dare Bioscience Inc
NASDAQ:DARE
0.508x
UMS Holdings Bhd
KLSE:7137
0.018x
Smart Concrete Public Company Limited
BK:SMART
0.028x
M VEST WATER NK-00227652
F:7YA
-0.105x
Salee Colour Public Company Limited
BK:COLOR
0.066x

Annual Cash Flow Conversion Efficiency for Urteste SA (2019–2025)

The table below shows the annual cash flow conversion efficiency of Urteste SA from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see URT stock market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 zł24.93 Million
≈ $6.86 Million
zł10.67 Million
≈ $2.94 Million
0.428x +288.70%
2024-12-31 zł24.11 Million
≈ $6.64 Million
zł-5.47 Million
≈ $-1.50 Million
-0.227x -18.22%
2023-12-31 zł27.74 Million
≈ $7.64 Million
zł-5.32 Million
≈ $-1.46 Million
-0.192x +71.57%
2022-12-31 zł5.62 Million
≈ $1.55 Million
zł-3.79 Million
≈ $-1.04 Million
-0.675x -154.05%
2021-12-31 zł9.69 Million
≈ $2.67 Million
zł-2.57 Million
≈ $-708.19K
-0.266x +73.22%
2020-12-31 zł1.37 Million
≈ $375.68K
zł-1.35 Million
≈ $-372.56K
-0.992x -197.46%
2019-12-31 zł1.20 Million
≈ $328.95K
zł-398.48K
≈ $-109.67K
-0.333x --

About Urteste SA

WAR:URT Poland Biotechnology
Market Cap
$18.19 Million
zł66.08 Million PLN
Market Cap Rank
#25395 Global
#255 in Poland
Share Price
zł43.30
Change (1 day)
+3.10%
52-Week Range
zł28.40 - zł70.20
All Time High
zł180.00
About

Urteste S.A. engages in the research and development of diagnostic tests for cancers. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, bile ducts, stomach, lung, esophagus, ovary, endometrium, blood, breast, and brain. The company was incorporated in 2021 and is based in Gdansk, Poland.